<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article id="papr13088" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Pain Pract</journal-id>
        <journal-id journal-id-type="iso-abbrev">Pain Pract</journal-id>
        <journal-id journal-id-type="pmc-domain-id">379</journal-id>
        <journal-id journal-id-type="pmc-domain">blackwellopen</journal-id>
        <journal-id journal-id-type="publisher-id">PAPR</journal-id>
        <journal-title-group>
          <journal-title>Pain Practice</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1530-7085</issn>
        <issn pub-type="epub">1533-2500</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Wiley Open Access Collection</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC9299475</article-id>
        <article-id pub-id-type="pmcid-ver">PMC9299475.1</article-id>
        <article-id pub-id-type="pmcaid">9299475</article-id>
        <article-id pub-id-type="pmcaiid">9299475</article-id>
        <article-id pub-id-type="pmid">34716965</article-id>
        <article-id pub-id-type="doi">10.1111/papr.13088</article-id>
        <article-id pub-id-type="publisher-id">PAPR13088</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="overline">
            <subject>Research Article</subject>
          </subj-group>
          <subj-group subj-group-type="heading">
            <subject>Research Articles</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>A retrospective study on patients with chronic knee pain treated with ultrasound‐guided radiofrequency of the genicular nerves (RECORGEN trial)</article-title>
          <alt-title alt-title-type="right-running-head">RECORGEN trial</alt-title>
          <alt-title alt-title-type="left-running-head">BELBA et al.</alt-title>
        </title-group>
        <contrib-group>
          <contrib id="papr13088-cr-0001" contrib-type="author">
            <name name-style="western">
              <surname>Belba</surname>
              <given-names initials="A">Amy</given-names>
            </name>
            <degrees>MD</degrees>
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9422-8940</contrib-id>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="papr13088-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0002" contrib-type="author">
            <name name-style="western">
              <surname>Vanneste</surname>
              <given-names initials="T">Thibaut</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0003" contrib-type="author">
            <name name-style="western">
              <surname>Van Kuijk</surname>
              <given-names initials="SMJ">Sander M. J.</given-names>
            </name>
            <degrees>PhD</degrees>
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2796-729X</contrib-id>
            <xref rid="papr13088-aff-0003" ref-type="aff">
              <sup>3</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0004" contrib-type="author">
            <name name-style="western">
              <surname>Mesotten</surname>
              <given-names initials="D">Dieter</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="papr13088-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0005" contrib-type="author">
            <name name-style="western">
              <surname>Mestrum</surname>
              <given-names initials="R">Roel</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="papr13088-aff-0004" ref-type="aff">
              <sup>4</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0006" contrib-type="author">
            <name name-style="western">
              <surname>Van Boxem</surname>
              <given-names initials="K">Koen</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0007" contrib-type="author">
            <name name-style="western">
              <surname>Van Lantschoot</surname>
              <given-names initials="A">Astrid</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0008" contrib-type="author">
            <name name-style="western">
              <surname>Bellemans</surname>
              <given-names initials="J">Johan</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="papr13088-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
            <xref rid="papr13088-aff-0005" ref-type="aff">
              <sup>5</sup>
            </xref>
            <xref rid="papr13088-aff-0006" ref-type="aff">
              <sup>6</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0009" contrib-type="author">
            <name name-style="western">
              <surname>Van de Velde</surname>
              <given-names initials="M">Marc</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="papr13088-aff-0007" ref-type="aff">
              <sup>7</sup>
            </xref>
            <xref rid="papr13088-aff-0008" ref-type="aff">
              <sup>8</sup>
            </xref>
          </contrib>
          <contrib id="papr13088-cr-0010" contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Van Zundert</surname>
              <given-names initials="J">Jan</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="papr13088-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="papr13088-aff-0009" ref-type="aff">
              <sup>9</sup>
            </xref>
            <address>
              <email>jan.van.zundert@mumc.nl</email>
            </address>
          </contrib>
        </contrib-group>
        <aff id="papr13088-aff-0001">
          <label>
            <sup>1</sup>
          </label>
          <named-content content-type="organisation-division">Department of Anesthesiology</named-content>
          <named-content content-type="organisation-division">Intensive Care Medicine, Emergency Medicine and Pain Therapy</named-content>
          <institution>Hospital Oost‐Limburg</institution>
          <city>Genk</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0002">
          <label>
            <sup>2</sup>
          </label>
          <named-content content-type="organisation-division">Faculty of Medicine and Life Sciences</named-content>
          <institution>Hasselt University</institution>
          <city>Diepenbeek</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0003">
          <label>
            <sup>3</sup>
          </label>
          <named-content content-type="organisation-division">Department of Clinical Epidemiology &amp; Medical Technology Assessment</named-content>
          <institution>Maastricht University Medical Centre</institution>
          <city>Maastricht</city>
          <country country="NL">The Netherlands</country>
        </aff>
        <aff id="papr13088-aff-0004">
          <label>
            <sup>4</sup>
          </label>
          <named-content content-type="organisation-division">Department of Anesthesiology</named-content>
          <named-content content-type="organisation-division">Intensive Care Medicine and Pain Therapy</named-content>
          <institution>Regional Hospital Heilig Hart Tienen</institution>
          <city>Tienen</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0005">
          <label>
            <sup>5</sup>
          </label>
          <institution>GRIT Belgian Sports Clinic</institution>
          <city>Leuven</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0006">
          <label>
            <sup>6</sup>
          </label>
          <named-content content-type="organisation-division">Department of Orthopedic Surgery</named-content>
          <institution>Hospital Oost‐Limburg</institution>
          <city>Genk</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0007">
          <label>
            <sup>7</sup>
          </label>
          <named-content content-type="organisation-division">Department of Anesthesiology</named-content>
          <institution>UZ Leuven</institution>
          <city>Leuven</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0008">
          <label>
            <sup>8</sup>
          </label>
          <named-content content-type="organisation-division">Department of Cardiovascular Sciences</named-content>
          <named-content content-type="organisation-division">Group Biomedical Sciences</named-content>
          <institution>KU Leuven</institution>
          <city>Leuven</city>
          <country country="BE">Belgium</country>
        </aff>
        <aff id="papr13088-aff-0009">
          <label>
            <sup>9</sup>
          </label>
          <named-content content-type="organisation-division">Department of Anesthesiology and Pain Medicine</named-content>
          <institution>University Medical Centre Maastricht</institution>
          <city>Maastricht</city>
          <country country="NL">The Netherlands</country>
        </aff>
        <author-notes>
          <corresp id="correspondenceTo">
            <label>*</label>
            <bold>Correspondence</bold>
            <break />
Jan Van Zundert, Department of Anaesthesiology &amp; Pain Medicine, Maastricht University Medical Centre, Postbus 5800, 6202 AZ Maastricht, The Netherlands.<break />
Email: <email>jan.van.zundert@mumc.nl</email>
            <break />
          </corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>09</day>
          <month>11</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>3</month>
          <year>2022</year>
        </pub-date>
        <volume>22</volume>
        <issue seq="50">3</issue>
        <issue-id pub-id-type="pmc-issue-id">412791</issue-id>
        <issue-id pub-id-type="doi">10.1111/papr.v22.3</issue-id>
        <fpage>340</fpage>
        <lpage>348</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="PAPR-22-340.pdf" />
        <self-uri content-type="pdf" ns0:href="file:PAPR-22-340.pdf" />
        <abstract id="papr13088-abs-0001">
          <title>Abstract</title>
          <sec id="papr13088-sec-0001">
            <title>Introduction</title>
            <p>Radiofrequency (RF) treatment of the genicular nerves is a promising treatment for chronic osteoarthritic and persistent postsurgical knee pain (PPSP), refractory to conventional medical management.</p>
          </sec>
          <sec id="papr13088-sec-0002">
            <title>Methods</title>
            <p>The RECORGEN study is a retrospective single‐center cohort study of patients treated with ultrasound‐guided conventional RF of the genicular nerves for chronic knee pain in Hospital Oost‐Limburg, Genk from September 2017 to June 2020. Subgroup analysis based on etiology of pain (PPSP and degenerative knee pain) was performed in addition to the total study population analysis. Outcome parameters were global perceived effect (GPE), Numeric Rating Scale for pain, consumption of strong opioids, and safety of the treatment at 6 weeks and cross‐sectionally at a variable time point. Treatment success was defined as GPE≥50%.</p>
          </sec>
          <sec id="papr13088-sec-0003">
            <title>Results</title>
            <p>Sixty‐eight cases were screened of which 59 (46 diagnosed with PPSP and 13 with degenerative knee pain) were included in the study. Treatment success at 6 weeks was achieved in 19 of 59 interventions (32.2%) and was similar in both groups. Seventeen responders were evaluated at follow‐up. 45.1% (8/17) continued to have a positive effect at the second time point. The mean duration of effect of the RF treatment was 8.3 months. Safety analysis at 6 weeks and at the second time point showed a good safety profile of the treatment.</p>
          </sec>
          <sec id="papr13088-sec-0004">
            <title>Conclusion</title>
            <p>Conventional RF of the genicular nerves was clinically successful in more than 30% of the study population refractory to conventional medical management. Overall, the treatment was well tolerated. The mean duration of effect was 8.3 months.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd id="papr13088-kwd-0001">chronic knee pain</kwd>
          <kwd id="papr13088-kwd-0002">genicular nerves</kwd>
          <kwd id="papr13088-kwd-0003">osteoarthritis</kwd>
          <kwd id="papr13088-kwd-0004">persistent postsurgical pain</kwd>
          <kwd id="papr13088-kwd-0005">radiofrequency ablation</kwd>
        </kwd-group>
        <funding-group>
          <award-group id="funding-0001">
            <funding-source>Belgian Association for Regional Anesthesia</funding-source>
            <award-id>BARA research grant Thibaut Vanneste</award-id>
          </award-group>
          <award-group id="funding-0002">
            <funding-source>Belgian Association for Regional Anesthesia (BARA)</funding-source>
          </award-group>
        </funding-group>
        <counts>
          <fig-count count="3" />
          <table-count count="3" />
          <page-count count="0" />
          <word-count count="6087" />
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY-NC</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>source-schema-version-number</meta-name>
            <meta-value>2.0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>cover-date</meta-name>
            <meta-value>March 2022</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>details-of-publishers-convertor</meta-name>
            <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:20.07.2022</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
      <notes>
        <p content-type="self-citation">
          <mixed-citation publication-type="journal" id="papr13088-cit-1001">
            <string-name name-style="western">
              <surname>Belba</surname>
              <given-names>A</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Vanneste</surname>
              <given-names>T</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Van Kuijk</surname>
              <given-names>SMJ</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Mesotten</surname>
              <given-names>D</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Mestrum</surname>
              <given-names>R</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Van Boxem</surname>
              <given-names>K</given-names>
            </string-name>, et al. <article-title>A retrospective study on patients with chronic knee pain treated with ultrasound‐guided radiofrequency of the genicular nerves (RECORGEN trial)</article-title>. <source>Pain Pract</source>.<year>2022</year>;<volume>22</volume>:<fpage>340</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1111/papr.13088</pub-id>
            <pub-id pub-id-type="pmid">34716965</pub-id>
            <pub-id pub-id-type="pmcid">PMC9299475</pub-id>
          </mixed-citation>
        </p>
      </notes>
    </front>
    <body id="papr13088-body-0001">
      <p>
        <boxed-text position="anchor" content-type="box" id="papr13088-blkfxd-0001" orientation="portrait">
          <caption>
            <title>Key points</title>
          </caption>
          <p>
            <list list-type="bullet" id="papr13088-list-0001">
              <list-item>
                <p>Radiofrequency treatment of the genicular nerves may be an alternative treatment that aims to reduce chronic knee pain and increase knee functionality in patients with therapy resistant osteoarthritis and persistent post‐surgical pain.</p>
              </list-item>
              <list-item>
                <p>Ultrasound‐guided radiofrequency treatment of the genicular nerves resulted in a significant improvement in approximately 30% of all patients suffering from degenerative knee pain and persistent post‐surgical pain. The success rates were similar in both groups.</p>
              </list-item>
              <list-item>
                <p>Ultrasound‐guided radiofrequency treatment has a low risk of serious side effects.</p>
              </list-item>
            </list>
          </p>
        </boxed-text>
      </p>
      <sec id="papr13088-sec-0005">
        <title>INTRODUCTION</title>
        <p>Osteoarthritis (OA) is a major health burden, which is largely attributable to knee osteoarthritis.<xref rid="papr13088-bib-0001" ref-type="bibr">
            <sup>1</sup>
          </xref> Usual treatment modalities for knee OA are physiotherapy, self‐management programs, lifestyle changes, knee braces, acupuncture, walking aids, and limited pharmacological treatment (oral analgesics like paracetamol, oral or topical nonsteroidal anti‐inflammatory drugs, and intra‐articular corticosteroids).<xref rid="papr13088-bib-0002" ref-type="bibr">
            <sup>2</sup>
          </xref> When conservative treatment is insufficient, non‐responders rely on surgery and/or on prescribed opioids despite their adverse effects. More than 50% of the population once diagnosed with knee OA will undergo a total knee arthroplasty (TKA) in their lifetime.<xref rid="papr13088-bib-0003" ref-type="bibr">
            <sup>3</sup>
          </xref> The fragile elderly with knee OA, however, often face a high intraoperative risk and the young OA population is confronted with repeated surgery due to the limited lifetime of a prothesis. Moreover, a considerable number of patients develops persistent post‐surgical knee pain (PPSP), a multifactorial and mostly neuropathic pain disorder.<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref> Twenty to fifty‐three percent of the patients develop chronic disabling pain after TKA that exists beyond the time for normal healing.<xref rid="papr13088-bib-0005" ref-type="bibr">
            <sup>5</sup>
          </xref>, <xref rid="papr13088-bib-0006" ref-type="bibr">
            <sup>6</sup>
          </xref>, <xref rid="papr13088-bib-0007" ref-type="bibr">
            <sup>7</sup>
          </xref>, <xref rid="papr13088-bib-0008" ref-type="bibr">
            <sup>8</sup>
          </xref>, <xref rid="papr13088-bib-0009" ref-type="bibr">
            <sup>9</sup>
          </xref> While recent studies have explored prediction tools to assess the risk of developing this complication, PPSP remains a condition with little treatment options.<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref>, <xref rid="papr13088-bib-0005" ref-type="bibr">
            <sup>5</sup>
          </xref>, <xref rid="papr13088-bib-0010" ref-type="bibr">
            <sup>10</sup>
          </xref>, <xref rid="papr13088-bib-0011" ref-type="bibr">
            <sup>11</sup>
          </xref>, <xref rid="papr13088-bib-0012" ref-type="bibr">
            <sup>12</sup>
          </xref>, <xref rid="papr13088-bib-0013" ref-type="bibr">
            <sup>13</sup>
          </xref>, <xref rid="papr13088-bib-0014" ref-type="bibr">
            <sup>14</sup>
          </xref> After a negative intensive orthopedic diagnostic approach, usual treatment consists of conservative therapy with analgesics and physiotherapy.<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref>, <xref rid="papr13088-bib-0015" ref-type="bibr">
            <sup>15</sup>
          </xref> The residual pain after TKA is most commonly located anteriorly.<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref>, <xref rid="papr13088-bib-0015" ref-type="bibr">
            <sup>15</sup>
          </xref>
        </p>
        <p>Radiofrequency (RF) treatment of the genicular nerves is a relatively novel and minimally invasive intervention that aims to reduce knee pain and increase knee functionality.<xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref>, <xref rid="papr13088-bib-0017" ref-type="bibr">
            <sup>17</sup>
          </xref> Firstly described by Choi et al.<xref rid="papr13088-bib-0018" ref-type="bibr">
            <sup>18</sup>
          </xref> in 2011, RF is a promising technique that could improve quality of life of patients with knee OA and PPSP.<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref> Conventional RF treatment targets the anterior sensory innervation of the knee, decreasing the transmission of pain signals by means of a thermal lesion. The targeted genicular nerves are the superomedial, inferomedial, and the superolateral genicular nerves which are branches of the femoral, saphenous, obturator, common peroneal, tibial, and sciatic nerves.<xref rid="papr13088-bib-0019" ref-type="bibr">
            <sup>19</sup>
          </xref>, <xref rid="papr13088-bib-0020" ref-type="bibr">
            <sup>20</sup>
          </xref>, <xref rid="papr13088-bib-0021" ref-type="bibr">
            <sup>21</sup>
          </xref>, <xref rid="papr13088-bib-0022" ref-type="bibr">
            <sup>22</sup>
          </xref> Until present, only minor localized adverse events (AEs) have been reported<xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref>, <xref rid="papr13088-bib-0017" ref-type="bibr">
            <sup>17</sup>
          </xref> but concern remains over long‐term desensitization of the knee leading to misuse and progression of OA.<xref rid="papr13088-bib-0023" ref-type="bibr">
            <sup>23</sup>
          </xref>, <xref rid="papr13088-bib-0024" ref-type="bibr">
            <sup>24</sup>
          </xref>
        </p>
        <p>The primary goal of this study is to evaluate the effectiveness of the ultrasound‐guided conventional RF treatment of the genicular nerves in patients who have chronic anterior knee pain due to PPSP or in patients who have a degenerative disease, and to estimate the duration of this effect. Secondary objectives are to evaluate the safety, the change in use of strong opioids, functional improvement, and the need of rescue therapy.</p>
      </sec>
      <sec sec-type="methods" id="papr13088-sec-0006">
        <title>METHODS</title>
        <sec id="papr13088-sec-0007">
          <title>Study design</title>
          <p>The RECORGEN study is a retrospective single‐center observational cohort of all patients treated with RF at the multidisciplinary chronic pain center in the Hospital Oost‐Limburg, Genk, between 1 September 2017 and 30 June 2020. The follow‐up period varied for each patient with a minimum of 6 weeks and a maximum of 27 months. The study protocol was approved by the ethical committee of the Hospital Oost‐Limburg (approval number 20/0005 U).</p>
        </sec>
        <sec id="papr13088-sec-0008">
          <title>Participants</title>
          <p>All consecutive patients with chronic knee pain who received RF treatment of the genicular nerves within the time frame were considered eligible. Patients who suffered from chronic widespread pain were excluded. The flow diagram is presented in Figure <xref rid="papr13088-fig-0001" ref-type="fig">1</xref>. Patients were divided into two subgroups following the etiology of pain: the PPSP group and the degenerative knee pain group (DP).</p>
          <fig position="float" fig-type="FIGURE" id="papr13088-fig-0001" orientation="portrait">
            <label>FIGURE 1</label>
            <caption>
              <p>Patient flow during the progression of the study</p>
            </caption>
            <graphic position="anchor" id="jats-graphic-1" orientation="portrait" ns0:href="PAPR-22-340-g002.jpg" />
          </fig>
        </sec>
        <sec id="papr13088-sec-0009">
          <title>Data collection and procedures</title>
          <p>The data were collected from the medical patient record at baseline and at 6 weeks after the procedure. For the follow‐up, only patients who had a successful treatment at 6 weeks received a questionnaire by mail in October 2020. A telephone contact was made 2 weeks later with those who did not respond. Informed consent for participation in the study was requested and obtained via mail. These data are further referred to as data of the second time point.</p>
          <p>Data collection was standardized by using patient case report forms in the online Castor data management tool. Each procedure per knee was considered a unique observation, and bilateral procedures were assessed specific for each treated knee. Data on patient level was gathered and analyzed per treated knee. We collected the following demographic and clinical data at baseline: age, sex, Numeric Rating Scale for pain (NRS), symptom duration, indication for the procedure, use of strong opioids and history of previous knee surgery. Strong opioid analgesics were defined as all opioids excluding tramadol and codeine. Data collected at 6 weeks post‐intervention included: NRS pain, global perceived effect (GPE), AEs, and concomitant use of strong opioids. GPE was expressed in percentage of improvement, ranging from 0–100%. Data at the second time point were only collected for patients who reported treatment success at 6 weeks, as the probability of symptom improvement after 6 weeks were considered negligible. Data collected at the second time point included the variables measured at 6 weeks after the procedure together with subjective functional outcome and data on other invasive treatments performed on the knee of interest in the time interval.</p>
        </sec>
        <sec id="papr13088-sec-0010">
          <title>RF procedure</title>
          <p>All patients underwent an ultrasound‐guided conventional RF treatment of the three genicular nerves (superomedial, inferomedial, and superolateral) after a positive diagnostic block (defined as at least 50% pain reduction) with lidocaine 2% 1 ml at each of the genicular nerves. Both procedures were executed under sterile conditions and no sedation was used. The used RF technique was like those previously reported in the literature.<xref rid="papr13088-bib-0025" ref-type="bibr">
              <sup>25</sup>
            </xref>, <xref rid="papr13088-bib-0026" ref-type="bibr">
              <sup>26</sup>
            </xref>, <xref rid="papr13088-bib-0027" ref-type="bibr">
              <sup>27</sup>
            </xref> Conventional RF was performed at a temperature of 70°C for 90 seconds per nerve after reaching a sensory threshold of less or equal to 0.5V and after excluding motor stimulation at 1.0V. The used RF probe was a 10 cm 21 G Cosman cannula with a 5‐mm active tip.</p>
        </sec>
        <sec id="papr13088-sec-0011">
          <title>Outcomes</title>
          <p>The primary endpoint was the proportion of patients with treatment success at week 6 defined as a GPE of ≥50% compared to baseline. Secondary endpoints were the proportion of patients with treatment success at the second time point, NRS reduction ≥50% compared to baseline at week 6 and at the second time point, subjective physical functioning at the second time point, long‐term treatment effect defined as the period with pain reduction, use of strong opioids at week 6 and at the second time point and rescue interventions. Outcomes were analyzed for the entire sample and according to the etiology of pain.</p>
          <p>Finally, adverse events were evaluated at both time points after RF treatment. Their number, type, and severity are included in the secondary endpoints.</p>
          <p>Efforts to address potential sources of bias were the following: One researcher (AB) performed the collection of data diminishing interobserver‐variability, and data were gathered in standardized patient report forms.</p>
        </sec>
        <sec id="papr13088-sec-0012">
          <title>Statistical analysis</title>
          <p>All data are presented for the whole cohort and stratified by DP and PPSP groups as mean values and standard deviation (SD), or as median values and interquartile range, depending on the distribution of the data. Groups were not compared to each other statistically as there were no a priori hypotheses on baseline differences.</p>
          <p>Treatment effect was described as success rates based on the GPE and NRS differences between baseline and post‐treatment scores of at least 50%, and was described as count and percentage with 95% confidence interval (CI). Within‐group change in NRS scores was tested using the paired‐samples <italic toggle="yes">t</italic> test for the whole cohort and stratified by group. As only one patient was treated bilaterally, no adjustment for correlated (multilevel) data was performed. Microsoft Excel version 16.0 and R version 4.0.4 were used for all analyses.</p>
        </sec>
      </sec>
      <sec sec-type="results" id="papr13088-sec-0013">
        <title>RESULTS</title>
        <sec id="papr13088-sec-0014">
          <title>Participant flow</title>
          <p>There were 68 procedures of conventional RF treatment of the genicular nerves of the knee after a positive diagnostic block. Sixty‐one cases were included in the study. Exclusion from the study was only due to presence of chronic widespread pain (<italic toggle="yes">n</italic> = 7). Fifty‐nine cases, 13 (22%) of the DP group and 46 (78%) of the PPSP group, completed the follow‐up period of 6 weeks, and two patients were lost to follow‐up. There were no other missing values for the primary endpoint. Nineteen of the 59 patients (32.2%) reported successful treatment at 6 weeks. These patients were contacted in October 2020, the outcome was analyzed at the second time point. The response rate to the questionnaire was 89%. The mean (±SD) time to follow‐up was 17 months (±10).</p>
        </sec>
        <sec id="papr13088-sec-0015">
          <title>Baseline characteristics</title>
          <p>Baseline demographic and clinical characteristics of the whole cohort, the DP group and the PPSP group separately are presented in Table <xref rid="papr13088-tbl-0001" ref-type="table">1</xref>. Seventy‐eight percent (46/59) of the cohort belonged to the PPSP group. Forty‐three of 46 cases developed PPSP after a TKA, and 15 of them underwent multiple TKA surgeries. The patients in the DP group suffered from OA (8/13), soft tissue (e.g., ligament) disease and posttraumatic pain. 27% of all patients used strong opioids.</p>
          <table-wrap position="float" id="papr13088-tbl-0001" content-type="Table" orientation="portrait">
            <label>Table 1</label>
            <caption>
              <p>Baseline data of the included patients expressed in mean values (±SD)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <col style="border-right:solid 1px #000000" span="1" />
              <col style="border-right:solid 1px #000000" span="1" />
              <col style="border-right:solid 1px #000000" span="1" />
              <col style="border-right:solid 1px #000000" span="1" />
              <thead valign="top">
                <tr style="border-bottom:solid 1px #000000">
                  <th align="left" valign="top" rowspan="1" colspan="1">Baseline data</th>
                  <th align="left" valign="top" rowspan="1" colspan="1">Degenerative knee pain (<italic toggle="yes">n</italic> = 13)</th>
                  <th align="left" valign="top" rowspan="1" colspan="1">PPSP (<italic toggle="yes">n</italic> = 46)</th>
                  <th align="left" valign="top" rowspan="1" colspan="1">All patients (<italic toggle="yes">n</italic> = 59)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Mean age (±SD) at baseline consultation</td>
                  <td align="left" rowspan="1" colspan="1">45.5 (±15.9)</td>
                  <td align="left" rowspan="1" colspan="1">66.9 (±13.9)</td>
                  <td align="left" rowspan="1" colspan="1">62.2 (±16.9)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Sex distribution, <italic toggle="yes">n</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                  <td align="left" rowspan="1" colspan="1">7 (53.8%)</td>
                  <td align="left" rowspan="1" colspan="1">33 (71.7%)</td>
                  <td align="left" rowspan="1" colspan="1">40 (67.8%)</td>
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                  <td align="left" rowspan="1" colspan="1">6 (46.2%)</td>
                  <td align="left" rowspan="1" colspan="1">13 (28.3%)</td>
                  <td align="left" rowspan="1" colspan="1">19 (32.2%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Index knee</td>
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Right</td>
                  <td align="left" rowspan="1" colspan="1">9 (69.2%)</td>
                  <td align="left" rowspan="1" colspan="1">18 (39.1%)</td>
                  <td align="left" rowspan="1" colspan="1">27 (45.8%)</td>
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left</td>
                  <td align="left" rowspan="1" colspan="1">4 (30.8%)</td>
                  <td align="left" rowspan="1" colspan="1">28 (60.9%)</td>
                  <td align="left" rowspan="1" colspan="1">32 (54.2%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patients on strong opioids at baseline consultation</td>
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                  <td align="left" rowspan="1" colspan="1" />
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No use of strong opioids</td>
                  <td align="left" rowspan="1" colspan="1">10 (76.9%)</td>
                  <td align="left" rowspan="1" colspan="1">33 (71.7%)</td>
                  <td align="left" rowspan="1" colspan="1">43 (72.9%)</td>
                </tr>
                <tr>
                  <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Use of strong opioids</td>
                  <td align="left" rowspan="1" colspan="1">3 (23.1%)</td>
                  <td align="left" rowspan="1" colspan="1">13 (28.3%)</td>
                  <td align="left" rowspan="1" colspan="1">16 (27.1%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Mean NRS (±SD) prior to RF treatment</td>
                  <td align="left" rowspan="1" colspan="1">7.8 (±1.7)</td>
                  <td align="left" rowspan="1" colspan="1">7.3 (±1.7)</td>
                  <td align="left" rowspan="1" colspan="1">7.4 (±1.8)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>The mean age (±SD) at baseline was 62 years (±16.9). Duration of knee pain before intervention followed an asymmetric distribution. The median duration of pain was 42 months (1<sup>st</sup> and 3<sup>rd</sup> quartile: 24 and 72 months). Three of 59 subjects underwent a second RF treatment at the index knee, while only one patient underwent the treatment on both knees.</p>
        </sec>
        <sec id="papr13088-sec-0016">
          <title>Effectiveness and duration of effect</title>
          <sec id="papr13088-sec-0017">
            <title>GPE</title>
            <p>At 6 weeks after treatment, 42.4% of all patients experienced some improvement in pain as expressed on the GPE. Treatment success (≥ 50% improvement of GPE) was achieved in 32.2% (95% CI: 20.6%–45.6%) of all 59 patients at week 6, with 30.8% (95% CI: 9.1%–61.4%) and 32.6% (19.5%–48.0%) success rate in the DP group and PPSP group respectively (Table <xref rid="papr13088-tbl-0002" ref-type="table">2</xref>). Treatment success at the second time point was obtained in 35.3% (95% CI: 14.2%–61.7%) of the patients who had treatment success at 6 weeks (Table <xref rid="papr13088-tbl-0003" ref-type="table">3</xref>). Interestingly, none of the three patients who underwent a second RF on the index knee reported treatment success after the second procedure while the patient who underwent RF in both knees did experience repeated treatment success.</p>
            <table-wrap position="float" id="papr13088-tbl-0002" content-type="Table" orientation="portrait">
              <label>Table 2</label>
              <caption>
                <p>Clinical outcomes at week 6 illustrated stratified by treatment group and for the complete cohort</p>
              </caption>
              <table frame="hsides" rules="groups">
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <thead valign="top">
                  <tr style="border-bottom:solid 1px #000000">
                    <th align="left" valign="top" rowspan="1" colspan="1">Clinical outcomes at week 6 per treatment group</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Degenerative knee pain</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">PPSP</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">All patients</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">GPE</td>
                    <td align="left" rowspan="1" colspan="1" />
                    <td align="left" rowspan="1" colspan="1" />
                    <td align="left" rowspan="1" colspan="1" />
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GPE 0–24%</td>
                    <td align="left" rowspan="1" colspan="1">6/13 (46.2%)</td>
                    <td align="left" rowspan="1" colspan="1">27/46 (58.7%)</td>
                    <td align="left" rowspan="1" colspan="1">33/59 (55.9%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GPE 25–49%</td>
                    <td align="left" rowspan="1" colspan="1">3/13 (23.1%)</td>
                    <td align="left" rowspan="1" colspan="1">3/46 (6.5%)</td>
                    <td align="left" rowspan="1" colspan="1">6/59 (10.2%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GPE 50–74%</td>
                    <td align="left" rowspan="1" colspan="1">2/13 (15.4%)</td>
                    <td align="left" rowspan="1" colspan="1">6/46 (13.0%)</td>
                    <td align="left" rowspan="1" colspan="1">8/59 (13.6%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GPE 75–100%</td>
                    <td align="left" rowspan="1" colspan="1">2/13 (15.4%)</td>
                    <td align="left" rowspan="1" colspan="1">9/46 (19.6%)</td>
                    <td align="left" rowspan="1" colspan="1">11/59 (18.6%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing data</td>
                    <td align="left" rowspan="1" colspan="1">0/13 (0%)</td>
                    <td align="left" rowspan="1" colspan="1">1/46 (2.1%)</td>
                    <td align="left" rowspan="1" colspan="1">1/59 (1.7%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment success (GPE ≥50%)</td>
                    <td align="left" rowspan="1" colspan="1">4/13 (30.8%)</td>
                    <td align="left" rowspan="1" colspan="1">15/46 (32.6%)</td>
                    <td align="left" rowspan="1" colspan="1">19/59 (32.2%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NRS</td>
                    <td align="left" rowspan="1" colspan="1" />
                    <td align="left" rowspan="1" colspan="1" />
                    <td align="left" rowspan="1" colspan="1" />
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NRS reduction ≥50%</td>
                    <td align="left" rowspan="1" colspan="1">4/13 (30.8%)</td>
                    <td align="left" rowspan="1" colspan="1">9/46 (19.6%)</td>
                    <td align="left" rowspan="1" colspan="1">13/59 (22.0%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean NRS (±SD) in treatment success (GPE ≥50%)</td>
                    <td align="left" rowspan="1" colspan="1">2.8 (±1.5)</td>
                    <td align="left" rowspan="1" colspan="1">3.4 (±1.7)</td>
                    <td align="left" rowspan="1" colspan="1">3.2 (±1.7)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean NRS (±SD) in treatment failure (GPE &lt;50%)</td>
                    <td align="left" rowspan="1" colspan="1">7.1 (±2.4)</td>
                    <td align="left" rowspan="1" colspan="1">7.5 (±1.5)</td>
                    <td align="left" rowspan="1" colspan="1">7.4 (±1.8)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Patients on strong opioids</td>
                    <td align="left" rowspan="1" colspan="1">3/13 (23.1%)</td>
                    <td align="left" rowspan="1" colspan="1">8/46 (17.4%)</td>
                    <td align="left" rowspan="1" colspan="1">11/59 (18.6%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Patients on strong opioids in treatment success group</td>
                    <td align="left" rowspan="1" colspan="1">1/4 (25%)</td>
                    <td align="left" rowspan="1" colspan="1">3/15 (20%)</td>
                    <td align="left" rowspan="1" colspan="1">4/19 (21.1%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Patients on strong opioids in treatment failure group</td>
                    <td align="left" rowspan="1" colspan="1">2/9 (22.2%)</td>
                    <td align="left" rowspan="1" colspan="1">5/31 (16.1%)</td>
                    <td align="left" rowspan="1" colspan="1">7/40 (17.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Adverse events</td>
                    <td align="left" rowspan="1" colspan="1">3/13 (23.1%)</td>
                    <td align="left" rowspan="1" colspan="1">6/46 (13%)</td>
                    <td align="left" rowspan="1" colspan="1">9/59 (15.3%)</td>
                  </tr>
                  <tr>
                    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe adverse events</td>
                    <td align="left" rowspan="1" colspan="1">0/13 (0%)</td>
                    <td align="left" rowspan="1" colspan="1">1/46 (2.2%)</td>
                    <td align="left" rowspan="1" colspan="1">1/59 (1.7%)</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <table-wrap position="float" id="papr13088-tbl-0003" content-type="Table" orientation="portrait">
              <label>Table 3</label>
              <caption>
                <p>Clinical outcomes at the second time point stratified by treatment group and for the complete cohort</p>
              </caption>
              <table frame="hsides" rules="groups">
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <col style="border-right:solid 1px #000000" span="1" />
                <thead valign="top">
                  <tr style="border-bottom:solid 1px #000000">
                    <th align="left" valign="top" rowspan="1" colspan="1">Clinical outcomes at the second time point</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Degenerative knee pain (<italic toggle="yes">n</italic> = 4)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">PPSP (<italic toggle="yes">n</italic> = 13)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">All patients (<italic toggle="yes">n</italic> = 17)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">GPE ≥50%</td>
                    <td align="char" char="(" rowspan="1" colspan="1">2/4 (50%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">4/13 (30.8%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6/17 (35.3%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Mean NRS (±SD)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">5.3 (±2.0)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">5.5 (±1.9)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">5.5 (±1.9)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Mean NRS (±SD) in patients with GPE ≥50%</td>
                    <td align="char" char="(" rowspan="1" colspan="1">4.0 (±0.0)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">3.8 (±2.2)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">3.8 (±1.8)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Mean NRS (±SD) in patients with GPE &lt;50%</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6.0 (±2.0)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6.6 (±0.8)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6.5 (±1.2)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Adverse events</td>
                    <td align="char" char="(" rowspan="1" colspan="1">0/4 (0%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">1/13 (7.7%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">1 /17 (5.9%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Patients on strong opioids</td>
                    <td align="char" char="(" rowspan="1" colspan="1">1/4 (25%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">5/13 (38.5%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6/17 (35.3%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Subjective increase in functionality</td>
                    <td align="char" char="(" rowspan="1" colspan="1">1/4 (25%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">6/13 (46.2%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">7/17 (41.2%)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Other interventional treatments of the knee</td>
                    <td align="char" char="(" rowspan="1" colspan="1">0/4 (0%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">2/13 (15.4%)</td>
                    <td align="char" char="(" rowspan="1" colspan="1">2/17 (11.8%)</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="papr13088-sec-0018">
            <title>NRS</title>
            <p>Mean NRS (±SD) of the whole cohort at baseline was 7.4 (±1.8) and reduced to 6.0 (±2.7) at 6 weeks, <italic toggle="yes">p</italic> = 0.001. The mean NRS of the patients included in the second follow‐up was 5.5 (±1.9), <italic toggle="yes">p</italic> = 0.034 compared to baseline. In the DP group, the mean NRS (±SD) at baseline was 7.8 (±1.8) and reduced to 5.6 (3.1) at 6 weeks (<italic toggle="yes">p</italic> = 0.029) while the mean NRS (±SD) in the PPSP group was 7.3 (±1.7) at baseline, which reduced to 6.1 (2.6) at 6 weeks (<italic toggle="yes">p</italic> = 0.008). The mean duration of effect (±SD) in the whole population was 8.3 (±6.8) months. Figure <xref rid="papr13088-fig-0002" ref-type="fig">2</xref> shows the distribution of pain scores for each of the follow‐up moments. Figure <xref rid="papr13088-fig-0003" ref-type="fig">3</xref> depicts evolution in the NRS score of all the patients that were followed up until the second time point.</p>
            <fig position="float" fig-type="FIGURE" id="papr13088-fig-0002" orientation="portrait">
              <label>FIGURE 2</label>
              <caption>
                <p>The average post‐treatment pain scores (NRS) using time since treatment as independent variable</p>
              </caption>
              <graphic position="anchor" id="jats-graphic-3" orientation="portrait" ns0:href="PAPR-22-340-g001.jpg" />
            </fig>
            <fig position="float" fig-type="FIGURE" id="papr13088-fig-0003" orientation="portrait">
              <label>FIGURE 3</label>
              <caption>
                <p>Evolution in pain intensity scores (NRS) during the follow‐up of all patients that were followed up until the second time point</p>
              </caption>
              <graphic position="anchor" id="jats-graphic-5" orientation="portrait" ns0:href="PAPR-22-340-g003.jpg" />
            </fig>
            <p>NRS reduction of ≥50% at week 6 was achieved in 13 (22%, 95% CI: 12.3%–34.7%) of all participants and this was still present in five of the 13 patients at the second time point (38.5%, 95% CI: 13.9%–68.4%). NRS reduction of ≥50% at week 6 was achieved in 4/13 (30.8%, 95% CI: 9.1%–61.4%) of DP participants, whereas NRS reduction of ≥50% at week 6 was achieved in 9/46 (19.6%, 95% CI: 9.4% ‐ 33.9%) of PPSP patients.</p>
            <p>Mean NRS (±SD) in the treatment success group at 6 weeks was 3.2 (±1.7) and 3.8 (±1.8) at the second time point. The mean difference from baseline to 6 weeks in NRS in the treatment success group was 4.1 (95% CI: 3.1–5.1, <italic toggle="yes">p </italic>&lt; 0.001), and the mean difference from baseline to the second time point was 1.6 (95% CI: 0.1–3.1, <italic toggle="yes">p</italic> = 0.034).</p>
          </sec>
          <sec id="papr13088-sec-0019">
            <title>Other</title>
            <p>Eight of seventeen (47.1%) of the subjects with treatment success at 6 weeks reported an increase in functionality at the second time point. Six of these patients also experienced improvement in pain. Two of the patients who had a temporary effect of RF treatment received rescue Platelet Rich Plasma therapy and intra‐articular corticosteroid injections. No patient underwent a TKA procedure during the observation period.</p>
          </sec>
        </sec>
        <sec id="papr13088-sec-0020">
          <title>Strong opioids</title>
          <p>At baseline, 16 (27.1%) of all patients used strong opioids. Only 11 (18.6%) of all patients needed the use of strong opioids at 6 weeks after treatment despite treatment success or failure. Seven of the 13 (53.8%) PPSP patients who used strong opioids at baseline continued to use them at 6 weeks. A single patient in the PPSP group started using strong opioids at 6 weeks. In the DP group, there were only three patients (23.1%) who used opioids at baseline, and they still relied on them at 6 weeks.</p>
          <p>Six (35.3%) of the patients followed up used strong opioids at the second time point. Compared to baseline, only two PPSP opioid naïve patients who did not experience any remaining treatment effect started to use strong opioids, while one PPSP patient stopped despite treatment failure. No changes in opioid use were noticeable in the DP group compared to baseline. Of the six patients who still experienced treatment effect at the second time point only one used strong opioids. Retrospectively, this patient also used strong opioids at baseline while the other five patients did not.</p>
        </sec>
        <sec id="papr13088-sec-0021">
          <title>Tolerability and safety</title>
          <p>At 6 weeks, four patients (6.8%) experienced hypoesthesia after the treatment. Other adverse events were only reported once: instability while walking, increase in pain, a self‐limiting hematoma, and a flare of complex regional pain syndrome (CRPS). Therapy‐related AE were thus registered in 15.3% of the patients at 6 weeks. CRPS in a PPSP patient was the only serious AE that was reported.</p>
          <p>Patients contacted at the second time point did not report new AEs. One person reported persistent paresthesia in the lateral knee.</p>
        </sec>
      </sec>
      <sec sec-type="discussion" id="papr13088-sec-0022">
        <title>DISCUSSION</title>
        <p>In this retrospective single‐center cohort study, we analyzed the effectiveness and safety of a conventional RF treatment of the genicular nerves in 13 patients with chronic anterior knee pain due to degenerative disease or other non‐surgical conditions in 13 patients and 46 PPSP patients during a maximum follow‐up of 27 months. This is to our knowledge the first study in a large population of PPSP patients. We report an overall clinical success of the RF treatment of 32%. This result was similar in each group. The mean duration (±SD) of the treatment effect was 8.3 (±6.8) months.</p>
        <p>Only 22% of the cases included in this study received RF treatment for degenerative knee pain. The success rates of RF of the genicular nerves in this group are considerably lower compared to previous studies of RF on knee OA.<xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref>, <xref rid="papr13088-bib-0018" ref-type="bibr">
            <sup>18</sup>
          </xref> Studies investigating RF in OA patients suggest that the conventional radiofrequency ablation has an average effectiveness of 65% three to 12 months after treatment.<xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref>, <xref rid="papr13088-bib-0018" ref-type="bibr">
            <sup>18</sup>
          </xref> This discordance may result from a learning curve after the introduction of a new technique, which evolved during the three years of the study. Another evident rationale is the heterogeneity of the patients in the DP group, including chronic knee pain of various origin such as soft tissue (e.g., ligament) disease and posttraumatic pain, refractory to conservative treatment, while in other studies, RF is mainly performed in patients with OA grade 2–4.<xref rid="papr13088-bib-0007" ref-type="bibr">
            <sup>7</sup>
          </xref>, <xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref> Additionally, the mean age of the analyzed group is remarkably younger than the mean age of the population presenting with knee OA pain. The average effectiveness data presented earlier is derived by studies performing predominantly fluoroscopy‐guided RF techniques.<xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref> Therefore, the execution of the RF technique using ultrasound‐imaging could have impacted the results; however, Sarı et al. showed similar clinical results when using ultrasound‐imaging compared with fluoroscopy.<xref rid="papr13088-bib-0028" ref-type="bibr">
            <sup>28</sup>
          </xref>, <xref rid="papr13088-bib-0029" ref-type="bibr">
            <sup>29</sup>
          </xref> All the previously mentioned parameters could influence the outcome of RF and further research should identify the best indications for RF of the knee.</p>
        <p>The majority (78%) of the analyzed population included were PPSP patients. To our knowledge, this is the largest study evaluating effectivity of RF in this subgroup. Baseline characteristics of PPSP patients indicate a marked dominance of females which is reported to be less in the literature.<xref rid="papr13088-bib-0030" ref-type="bibr">
            <sup>30</sup>
          </xref> The predominant surgery that preceded PPSP was a TKA. We report a 32.6% success rate of the conventional RF treatment in the PPSP group at 6 weeks. Ogalla et al.<xref rid="papr13088-bib-0031" ref-type="bibr">
            <sup>31</sup>
          </xref> reported a reduction in visual analogue scale scores of &gt;50% in 75% of the 16 analyzed PPSP patients at 1 month and 65% at 6 months in a prospective observational study. Qudsi‐Sinclair et al.<xref rid="papr13088-bib-0032" ref-type="bibr">
            <sup>32</sup>
          </xref> published the only RCT on RF for PPSP comparing conventional RF to intra‐articular injections with local anesthetics and corticosteroid. Efficacy in pain scores, disability, and quality of life was similar in all 28 patients at 3–6 months with a mean NRS reduction (±SD) of 2.6 (±2.7) at 6 months after RF treatment. Additionally, two isolated case reports by Protzman et al.<xref rid="papr13088-bib-0033" ref-type="bibr">
            <sup>33</sup>
          </xref> and by Metnzies et al.<xref rid="papr13088-bib-0006" ref-type="bibr">
            <sup>6</sup>
          </xref> show positive results of conventional and cooled RF at 3 and at 9 months.</p>
        <p>The result of our study on PPSP is less encouraging than the previous publications on PPSP.<xref rid="papr13088-bib-0031" ref-type="bibr">
            <sup>31</sup>
          </xref>, <xref rid="papr13088-bib-0032" ref-type="bibr">
            <sup>32</sup>
          </xref>, <xref rid="papr13088-bib-0033" ref-type="bibr">
            <sup>33</sup>
          </xref> This study shows possible important differences in effectiveness of RF treatment of the genicular nerves in a real‐world setting compared to prospective studies. One probable noteworthy factor is that physician performance is influenced by increasing experience, especially in such innovative interventions. Another important consideration is the possible abnormal nerve growth and altered location of the genicular nerves after surgery which could make them difficult to target in PPSP patients. Furthermore, the different pathophysiological mechanisms of PPSP compared to OA, outlining PPSP of a predominantly neuropathic nature,<xref rid="papr13088-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref>, <xref rid="papr13088-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref> might be accountable for this variation in effectiveness.</p>
        <p>Traditionally, the superomedial, superolateral, and inferomedial genicular nerves are targeted during the RF procedure. Recent anatomical studies of the knee innervation indicate that there are 10 genicular nerves that innervate the anterior knee and that anatomical variations exist.<xref rid="papr13088-bib-0021" ref-type="bibr">
            <sup>21</sup>
          </xref>, <xref rid="papr13088-bib-0035" ref-type="bibr">
            <sup>35</sup>
          </xref>, <xref rid="papr13088-bib-0036" ref-type="bibr">
            <sup>36</sup>
          </xref> The cadaver study of Fonkoue et al.<xref rid="papr13088-bib-0036" ref-type="bibr">
            <sup>36</sup>
          </xref> proposes revised anatomical landmarks for the original genicular nerves. Chen et al.<xref rid="papr13088-bib-0037" ref-type="bibr">
            <sup>37</sup>
          </xref> and McCormick et al.<xref rid="papr13088-bib-0035" ref-type="bibr">
            <sup>35</sup>
          </xref> advocate that ablation of up to ten genicular nerves could improve outcomes of this treatment. Future clinical trials incorporating this improved knowledge of the innervation of the knee are necessary for optimalization of the RF technique for chronic knee pain.</p>
        <p>While we defined success in this study as GPE≥50%, frequently used definitions in the literature are a decrease of ≥50% in a pain intensity scores like NRS and values of knee composite scores.<xref rid="papr13088-bib-0007" ref-type="bibr">
            <sup>7</sup>
          </xref>, <xref rid="papr13088-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref> The choice of the GPE in this study was dictated from the clinical practice of the hospital where this score is used to assess a favorable outcome.</p>
        <p>Concerns on RF safety are addressed in this study by means of a mean (±SD) follow‐up of 17 months (±10). At 6 weeks after treatment, the most frequent AE was hypoesthesia in four cases. One patient belonging to the PPSP group experienced a flare of CRPS which was considered a serious AE. Patients contacted at the second time point did not report new AEs. Paresthesia was persistent in one PPSP patient and temporary in two of the patients who were followed up until the second time point after reporting it at week 6. Reassuringly, the number of complications was lower in the PPSP group compared to the DP group.</p>
        <p>Regarding medication use, patients used less strong opioids at 6 weeks after treatment in both groups despite treatment success or failure. Arguably, this is due to the information patients received on adequate treatment of non‐oncologic pain by the pain clinician. Strong opioid use increased at the second time point. However, data should be regarded with caution as this study included a broad range of ages, where elderly had multiple comorbidities or pain problems.</p>
        <p>One of the limitations of this study is inherent to its retrospective nature. The data gathered on pain, functionality scores and medication were limited to the annotations in a non‐standardized medical record. We could not gather objective evaluation of knee function and recall bias might influence the results of duration of the effect of the treatment. A second limitation is that comparison with previous studies is difficult due to the use of ultrasound as guidance for the procedure as most of the studies use fluoroscopy‐guided RF. Another limitation concerns the subgroup analysis of degenerative knee pain. These results need to be interpreted with caution due to the small number of patients included in this group.</p>
        <p>The major strength of this study is that it represents real‐world data with a large population of primarily PPSP patients. The findings of this study suggest that anatomic changes and different pathophysiological mechanisms of pain in this group could result in a lower success rate of conventional RF. Future studies should address this concern.</p>
        <p>In conclusion, the observational data presented in this study position conventional RF treatment of the genicular nerves of the knee as a relatively effective and safe therapy in more than 30% of patients suffering from refractory degenerative pain and PPSP.</p>
      </sec>
      <sec sec-type="COI-statement" id="papr13088-sec-0024">
        <title>CONFLICT OF INTEREST</title>
        <p>The authors have no conflict of interest to declare.</p>
      </sec>
      <sec id="papr13088-sec-0025">
        <title>DISCLAIMERS</title>
        <p>The authors state that the expressed views are original and not an official position of the institution or funder.</p>
      </sec>
    </body>
  </article>
</pmc-articleset>